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2010CARD14 Gain-of-Function Mutation Alone
Is Sufficient to Drive IL-23/IL-17eMediated
Psoriasiform Skin Inflammation In Vivo
Mark Mellett1,4, Barbara Meier1, Deepa Mohanan1, Rebekka Schairer2, Phil Cheng1, Takashi K. Satoh1,
Betina Kiefer1, Caroline Ospelt3, Stephan Nobbe1, Margot Thome2, Emmanuel Contassot1 and
Lars E. French1,4Rare autosomal dominant mutations in the gene encoding the keratinocyte signaling molecule CARD14, have
been associated with an increased susceptibility to psoriasis, but the physiological impact of CARD14 gain-of-
function mutations remains to be fully determined in vivo. Here, we report that heterozygous mice harboring a
CARD14 gain-of-function mutation (Card14DE138) spontaneously develop a chronic psoriatic phenotype with
characteristic scaling skin lesions, epidermal thickening, keratinocyte hyperproliferation, hyperkeratosis, and
immune cell infiltration. Affected skin of these mice is characterized by elevated expression of anti-microbial
peptides, chemokines, and cytokines (including T helper type 17 cell-signature cytokines) and an immune
infiltrate rich in neutrophils, myeloid cells, and T cells, reminiscent of human psoriatic skin. Disease patho-
genesis was driven by the IL-23/IL-17 axis, and neutralization of IL-23p19, the key cytokine in maintaining
T helper type 17 cell polarization, significantly reduced skin lesions and the expression of antimicrobial pep-
tides and proinflammatory cytokines. Therefore, hyperactivation of CARD14 alone is sufficient to orchestrate
the complex immunopathogenesis that drives T helper type 17-mediated psoriasis skin disease in vivo.
Journal of Investigative Dermatology (2018) 138, 2010e2023; doi:10.1016/j.jid.2018.03.1525INTRODUCTION
Psoriasis is a common chronic inflammatory disease of the
skin that is estimated to affect approximately 2% of the global
population and is equally prevalent in males and females
(Christophers, 2001; Gudjonsson and Elder, 2007). Psoriasis
is characterized by scaly erythematous plaques on the skin,
which, given its chronic course, significantly impairs the
quality of life of affected individuals. The most common form
of psoriasis is psoriasis vulgaris (plaque psoriasis), but other
forms exist with distinct clinical features, including guttate
psoriasis, pustular psoriasis, and palmoplantar psoriasis
(Griffiths and Barker, 2007). Overall, 20e30% of plaque
psoriasis cases are associated with debilitating psoriatic
arthritis, and psoriasis patients can suffer from comorbidities
including cardiovascular disease, diabetes, and obesity
(Griffiths and Barker, 2007; Mease et al., 2013). Histological
hallmarks of psoriasis include epidermal acanthosis, kerati-
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an open access artcell infiltration, and angiogenesis. Disease symptoms arise
from a complex interaction between keratinocytes and infil-
trating immune cells (Bos and De Rie, 1999; Boyman et al.,
2007; Sano et al., 2005; Valdimarsson et al., 1995). How-
ever, the early triggers that lead to full-blown disease are not
well understood, confounded by the wide range of genetic
factors that contribute to an elevated risk of developing
psoriasis, including genes controlling epidermal barrier
integrity (e.g., LCE3B, LCE3D) and antigen presentation (e.g.,
HLA-Cw*0602, ERAP1) and genes of the innate (e.g.,
NFKBIA) and adaptive immune systems (e.g., IL12B, IL23R)
(Tsoi et al., 2012). Although genome-wide association studies
have shown that approximately more than 80 genes in
Caucasian and Han Chinese populations are associated with
an increased susceptibility to psoriasis, very few genetic
variants have actually been studied in vivo (Sheng et al.,
2014; Tsoi et al., 2017).
Rare autosomal dominant mutations in the gene encoding
a keratinocyte scaffold molecule, CARD14 (which maps to
the PSORS2 locus) have been associated with a number of
psoriatic phenotypes including plaque psoriasis and psoriatic
arthritis, generalized pustular psoriasis, and palmoplantar
pustular psoriasis, in addition to familial and sporadic cases
of the clinically related but rare disease pityriasis rubra pilaris
(PRP) (Fuchs-Telem et al., 2012; Has et al., 2016; Hong et al.,
2014; Jordan et al., 2012a, 2012b; Li et al., 2015; Mossner
et al., 2015; Sugiura et al., 2014; Takeichi et al., 2017a,
2017b). CARD14 is a proinflammatory signaling molecule
whose expression is predominantly restricted to the placenta
and keratinocytes of the skin, although CARD14 expression
was also reported on CD31-positive endothelial cells (Fuchs-
Telem, 2012; Harden et al., 2014). CARD14 is the seconds. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology. This is
icle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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family (Bertin et al., 2001; Scudiero et al., 2014). CARMA
proteins contain CARD, coiled-coil, SH3, and guanylate
kinase-like domains, and they exist in an auto-inhibitory
state. In response to external stimuli, CARMA proteins are
phosphorylated via protein kinase C isoforms (Scudiero et al.,
2014). Subsequently, they undergo a conformational change,
facilitating recruitment of the interacting partners Bcl10 (via
CARD:CARD domain interactions) and Malt1 to form the
CARMA:Bcl10:Malt1 (i.e., CBM) signaling complex, or “sig-
nalosome” (Bertin, 2001; Gaide et al., 2001; Howes et al.,
2016; Jattani et al., 2016; McAllister-Lucas et al., 2001;
Scudiero, 2014). CARD11 (CARMA1), expressed in lymphoid
cells, is activated upon B- and T-cell receptor engagement,
and gain-of-function (GoF) mutations in the genes encoding
CARD11, Bcl10, and Malt1 have been associated with a
number of lymphoid malignancies (Gaide, et al., 2002;
Juilland and Thome, 2016; Pomerantz et al., 2002; Wang
et al., 2002). Similarly, CARD10 (CARMA3), expressed in
epithelial tissue and activated by G protein-coupled receptor
stimulation, has been linked to the progression of various
carcinomas (Du et al., 2014; Pan et al., 2016; Xia et al., 2016;
Xie et al., 2014).
CARD14 was recently described to be activated in vitro in
response to zymosan and Staphylococcus aureus pathogen-
associated molecular pattern agonists (Schmitt et al., 2016;
Scudiero et al., 2017). Therefore, CARD14 likely plays its
main role in innate immune defense, which is supported by
the genes activated downstream of CARD14, which typically
encode for proinflammatory cytokines and chemokines,
including IL-36g, IL-8, and Ccl20 (Jordan, 2012a). The
contribution of CARD14 GoF to psoriatic disease pathogen-
esis, however, remains unclear. CARD14 mutations are rare,
and some polymorphisms (p.Arg820Trp, p.Arg547Ser) asso-
ciated with PRP in a Taiwanese study were also shown to be
present in the general population (Hong, 2014). Other
polymorphisms (p.Gly117Ser) have shown phenotypes that
vary considerably, with respect to age of onset and severity,
raising the possibility that other genetic or environmental
factors may be required (Jordan, 2012b).
Mutation or deletion of a single glutamic acid (E138) in the
coiled-coil domain of CARD14 has been associated with
both psoriasis and PRP (Fuchs-Telem, 2012; Has, 2016; Inoue
et al., 2016; Jordan, 2012b). These variants resulted in severe
phenotypes and add support to the relevance of CARD14
mutations to an increased risk of psoriatic skin disease.
However, the contribution of CARD14 to psoriasis patho-
genesis remains open, and therefore we sought to determine
the functional impact of CARD14 E138 mutation in vivo.
RESULTS
CARD14 GoF mutation causes spontaneous signalosome
formation in primary human keratinocytes, which is
dependent on a functional CARD domain
Consistent with previous reports, CARD14 E138A and DE138
mutants both caused enhanced NF-kB and AP-1 activation
in vitro in HEK293 cells compared with wild-type (WT)
CARD14, with the E138A mutant showing a more potent
response (see Supplementary Figure S1a online) (Afonina
et al., 2016; Li et al., 2015). CARD14 E138A and CARD14DE138 GoF mutants were also overexpressed in primary
keratinocytes and HEK293 cells and were observed to
interact with endogenous Bcl10 by co-immunoprecipitation
(Figure 1a, and see Supplementary Figure S1b), whereas
Bcl10 interaction with CARD14 WT was below detectable
levels. Because this was contrary to previous findings
(Afonina, 2016; Scudiero, 2011), we sought to assess other
means of CARD14 activity. There was a reduction of Bcl10
expression observed in the presence of all three CARD14
constructs in HEK293 cells (see Supplementary Figure S1b)
and a decrease of CARD14 mutant expression in primary
keratinocytes (Figure 1a). Previously, it has been suggested
that CARD14 mutants associated with psoriasis are less sol-
uble than WT CARD14 (Berki et al., 2015). Additionally, it
has been previously described that Bcl10 forms oligomeric
structures that can be nucleated by CARD11 (Qiao et al.,
2013). It was therefore of interest to determine whether
interaction of CARD14 with Bcl10 can induce nucleation and
insolubility of the latter. First, we assessed whether mutation
of the CARD14 CARD domain could diminish downstream
effects. The CARD14 R38 residue has been previously
described to be at the Bcl10-interacting interface, and sub-
stitution of arginine R38 with cysteine in the CARD domain
was previously reported to lack the ability to activate NF-kB
(Jordan, 2012b; Qiao, 2013); therefore, it was anticipated
that the R38C mutation would abolish CARD:CARD in-
teractions. Indeed, mutation of the R38 residue in the
CARD14 E138A construct completely abrogates the ability of
the E138A mutant to interact with Bcl10 (see Figure 1b,
Supplementary Figure S1c) and to potently activate NF-kB
and AP-1 in HEK293 cells (see Supplementary Figure S1d).
R38C mutation also diminished the ability of CARD14 E138A
to drive IL-8 production in primary keratinocytes (see
Supplementary Figure S1e).
To assess nucleation of Bcl10 in the presence of CARD14
GoF mutants, primary keratinocytes were transfected with
CARD14 WT, CARD14 E138A, and CARD14 R38C/E138A.
Cells were lysed in Triton X-100econtaining buffer (Sigma
Aldrich, St. Louis, MI), and Triton-insoluble and soluble
fractions were assessed by SDS-PAGE. As expected, mutant
CARD14 variants were found at higher levels in the insoluble
fraction than WT CARD14. Moreover, levels of Bcl10 were
more highly increased in the insoluble fraction in the pres-
ence of CARD14 E138A compared with CARD14 WT, and
this was dependent on a functional CARD domain
(Figure 1c), also consistent with a previous report (Bertin
et al., 2001).
Insoluble mutant CARD14 E138A and CARD14 DE138/
Bcl10 complexes or “signalosomes” are visible by confocal
microscopy in primary keratinocytes (Figure 1d), whereas
CARD14 WT was more widely expressed throughout the
cytoplasm, consistent with its weak interaction with Bcl10 in
co-immunoprecipitation studies. CARD14 R38C/E138A
retained the ability to form insoluble oligomers (Figure 1c
and d), but it failed to recruit Bcl10 to these complexes in
primary keratinocytes (Figure 1d).
Spontaneous signalosome formation induced by CARD14
E138A and CARD14 DE138 resulted in enhanced Malt1
para-caspase activity in HEK293 cells, as measured using a
previously described fluorescence resonance energy transfer-www.jidonline.org 2011
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Figure 1. Mutation of Card14 E138 causes spontaneous signalosome assembly in primary keratinocytes and is dependent on a functional CARD domain. (a, b)
Primary keratinocytes were transfected with Myc-tagged CARD14 WT, CARD14 E138A, and (a) CARD14 DE138 or (b) CARD14 R38C/E138A for 24 hours. Cell
lysates were immunoprecipitated with an anti-Bcl10 antibody, followed by immunoblotting with indicated antibodies. (c) Human primary keratinocytes were
transfected for 24 hours with Myc-tagged CARD14 WT, CARD14 E138A, or CARD14 R38C/E138A. Cells were lysed in Triton X-100econtaining buffer, and
soluble and insoluble fractions were subject to SDS-PAGE followed by immunoblotting with indicated antibodies. (d) Human primary keratinocytes were
transfected for 24 hours with Myc-tagged CARD14 WT, CARD14 E138A, CARD14 DE138, or CARD14 R38C/E138A and visualized for expression and
localization by confocal microscopy using specific anti-Myc and anti-Bcl10 antibodies. Nuclei were stained with DAPI. Scale bar ¼ 15 mm. (e) Flow cytometry
analysis and immunoblot analysis of HEK293T cells transfected with increasing amounts of Myc-tagged CARD14 constructs with Strep-tagged Malt1 and the
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Figure 2. Card14DE138D/e
heterozygous mice develop a
spontaneous psoriatic phenotype.
(a) 8-week-old Card14DE138þ/e
heterozygous mice develop dry skin
around the eyes and whiskers and dry
flaky skin on the ears and tail. (b) Ear
thickness (mm) of Card14DE138þ/e
and wild-type littermates measured
with microcalipers (n ¼ 9 per group).
(c) Card14DE138þ/e mice and wild-
type littermates were weighed at 8
weeks old (n ¼ 8 per group). (def, h)
Hematoxylin and eosin staining
of ear sections from 8-week-old
Card14DE138þ/e and wild-type mice.
Arrows show (e) parakeratosis (arrow)
and orthokeratosis (arrowhead), (f)
microabscess, and (h) blood vessels.
Scale bar ¼ 300 mm in d or 100 mm
in e, f, and h. (g) Ear sections from
8-week-old Card14DE138þ/e mice
stained with a specific anti-Ly6G
antibody or isotype control. Scale
bar ¼ 100 mm. (i) Ear sections from
8-week-old Card14DE138þ/e and
wild-type littermates were stained
with specific antibodies against Ki67,
keratin-14, and keratin-1. Images
(a) are representative of all
Card14DE138þ/e heterozygous mice
observed or (dei) are representative
of 8 individual mice per group, or
(b, c) each data point represents an
individual mouse and was subjected
to a two-tailed unpaired Student t test,
****P < 0.0001. ns, nonsignificant;
WT, wild type.
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previous reports (Afonina, 2016; Howes, 2016). Malt1 dis-
played augmented catalytic activity in the presence of
CARD14 E138A and CARD14 DE138 mutants comparedEYFP-LVSR-eCFP reporter plasmid for 24 hours. (f) Human primary keratinocytes w
were subject to immunoblotting with anti-Myc, anti-IL-36g, and anti-b-actin ant
immunoblot; IP, immunoprecipitation; WT, wild type.with WT (Figure 1e). However, CARD14 R38C/E138A lost
the ability to stimulate Malt1 activity beyond basal levels.
In primary keratinocytes, CARD14 E138A and CARD14
DE138 mutants drive production of IL-36g; however, againere transfected for 24 hours with Myc-tagged CARD14 constructs. Cell lysates
ibodies. Data in aef are representative of three independent experiments. IB,
www.jidonline.org 2013
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2014disruption of the CARD domain abolishes this effect
(Figure 1f).
Mutation of Card14 E138 causes spontaneous psoriasiform
disease in mice
To define the physiological impact of CARD14 E138 GoF
mutation in potentially driving psoriasis pathogenesis, a
transgenic mouse incorporating deletion of the E138 residue
of CARD14 was generated using CRISPR/Cas9 technology
(see Supplementary Figure S2a and b). The Card14DE138
mutation was chosen because it displayed less potent acti-
vation of NF-kB, and it was speculated that these mice might
be less likely to suffer unwanted defects due to hyperactive
NF-kB activity. Card14DE138 heterozygous mice appeared
indistinguishable from WT littermates at birth (see
Supplementary Figure S2c) but developed dry flaky skinJournal of Investigative Dermatology (2018), Volume 138patches on the back at 5 days of age, which began to
disappear at 7 days. However, this progressed to the devel-
opment of thickened squamous skin on the tail (between 2
and 3 weeks) and, finally, the ears (at 4e5 weeks), reminis-
cent of human psoriasis skin lesions (see Supplementary
Figure S2d and e). Adult mice showed a chronic psoriatic
phenotype with thickened squamous skin of the ears and tail
and dry skin around the eyes and whiskers, affecting 100% of
heterozygous male and female mice (Figure 2a). Ear thickness
was significantly increased in Card14DE138þ/e mice
compared with WT littermates (Figure 2b). There was no
significant difference in weight in Card14DE138þ/e adult
mice compared with WT littermates (Figure 2c).
Hematoxylin and eosin staining of ear tissue from
Card14DE138þ/e mice showed acanthosis due to keratino-
cyte hyperproliferation and immune cell infiltration of the
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parakeratosis (arrow) and orthokeratosis (arrowhead), and
keratotic follicular plugging (see Supplementary Figure S3a
online), all hallmarks of human psoriatic skin disease. Simi-
larly, tail skin showed marked hyperplasia (see
Supplementary Figure S3b) with increased thickening of the
epidermis and immune cell infiltration. In addition to a clear
increase in infiltrate of immune cells, the presence of
microabscesses was also observed in the epidermis of
Card14DE138þ/e mice (Figure 2f). Positive staining with the
neutrophil marker Ly6G indicated that neutrophils make up
the composition of these microabscesses (Figure 2g). An
increased number of enlarged CD31-positive blood vessels
were also histologically observed in the dermis, indicating an
increase in the dermal vasculature in psoriatic tissue from
Card14DE138þ/e mice (Figure 2h, and see Supplementary
Figure S3c). In Card14DE138þ/emice, basal keratinocytes
showed strong and abundant expression of the proliferation
marker Ki67, indicating hyperproliferation of keratinocytes in
the basal layer (Figure 2i, and see Supplementary Figure S3d).
Similarly, keratin-14 expression, a marker for the proliferative
basal layer of the epidermis, was no longer restricted to basal
keratinocytes, as in WT mice, but also present in suprabasal
layers, typical of human psoriasis. Expression of keratin-1 (an
indicator of early keratinocyte differentiation), which was
localized in the suprabasal layer of WT mice, is increased
and expressed throughout the epidermis in Card14DE138þ/e
mouse skin. Card14DE138 homozygous mice displayed
development abnormalities (see Supplementary Figure S4a
online) and increased mortality. Surviving neonates were
runts (see Supplementary Figure S4b) and died after a few
days, typically with a very marked psoriatic phenotype (see
Supplementary Figure S4c and d). Toluidine blue staining was
performed to determine whether neonates had a skin barrier
defect and an increase in skin permeability. Toluidine blue
dye failed to stain the epidermis, indicating that neither
homozygous nor heterozygous pups had an epidermal barrier
defect (see Supplementary Figure S4e).
CARD14 GoF mutation in vivo results in a transcriptomic
gene profile similar to human plaque psoriasis
To obtain a comprehensive overview of the transcriptional
signature of the inflammatory milieu driving disease patho-
genesis in Card14DE138þ/e mice, RNA was extracted from
ear tissue of 8-week-old mice and subjected to RNA
sequencing analysis (Figure 3aec). Differentially expressed
genes from the psoriatic tissue of Card14DE138þ/e mice
included up-regulated hyperproliferative keratins (Krt6a,
Krt6b, Krt16); antimicrobial peptides including b-defensins
(Defb3, Defb4, Defb14), S100 proteins (S100a7, S100a8,
S100a9), and lipocalin-2 (Lcn2); and mRNA-encoding cyto-
kines of the innate (IL-1a, IL-1b, IL-36a, IL-36b, IL-36g, IL-6,
and IL-17C) and adaptive (IL-20, IL-22, IL-23p19, and IL-17F)
immune systems. IL-20 family member IL-19, a cytokine
previously shown to be up-regulated in serum and tissue of
psoriasis patients and a key component of the IL-23/IL-17A
axis, was one of the most highly up-regulated cytokines.
IL-19 was shown previously to be specifically expressed by
keratinocytes and acts in an autocrine manner in synergy
with IL-17A to further enhance induction of anti-bacterialS100 proteins (Romer et al., 2003; Witte et al., 2014). Up-
regulation of chemokines was also evident, including Ccl20
and the neutrophil chemoattractants Cxcl1, Cxcl2, Cxcl3,
and Cxcl5. This transcriptional signature likely also reflects
secondary changes in dermal endothelial cells and infiltrating
immune cells. IL-1 family cytokines, including receptor
antagonists, NOD2, caspase-1, caspase-4, and NLRP3, are
all up-regulated in Card14DE138þ/e psoriatic tissue, indi-
cating that this phenotype is very much dependent on auto-
inflammatory and autoimmunity networks.
Psoriatic tissue from Card14DE138þ/e mice also showed
high expression of early cornified envelope proteins
including involucrin (Ivl) and IL-17Aeinduced small proline
rich proteins (Sprr2b and Sprr2d). The S100-interacting pro-
tein Fabp5 is also increased. Late cornified envelope proteins
including Lce3b and Lce3d show high expression, and the
serine protease inhibitors Sepinb3a, Sepinb3c, and Sepina9
are also highly up-regulated. Down-regulated differentially
expressed genes include keratin-2 and -24, serpin3b, and
serpin12. Filaggrin-2 was also down-regulated, inversely
correlating with filaggrin-1 expression in this model. IL-38
(Ilf10), an anti-inflammatory cytokine that specifically
inhibits IL-36 cytokines, was also down-regulated in
Card14DE138þ/e psoriatic tissue, suggesting that in psoriatic
skin disease, increased activity of IL-36 cytokines is likely
additionally enhanced by decreased expression of this
endogenous inhibitor.
We performed pathway analysis and found that keratini-
zation, formation of the cornified envelope, signaling by
interleukins, and antimicrobial peptides were enriched
functions among up-regulated genes (Figure 3c). Comparing
transcriptome analysis from Card14DE138þ/e mice with
that of human plaque psoriasis available from the publica-
tions of Li et al. (2014) (GSE54456) and Keermann et al.
(2015) (GSE6651), there is positive enrichment of up-
regulated genes with both human studies and negative
enrichment of down-regulated genes (Figure 3d). This cor-
relation shows that the transcriptional landscape induced by
CARD14 GoF mutation in vivo is typical of human plaque
psoriasis.
To further confirm transcriptomic data and to analyze the
expression of proinflammatory genes at the onset of macro-
scopic skin changes in Card14DE138þ/e mice, RNA was
extracted from ear tissue of 5-week-old Card14DE138þ/e
mice and analyzed by quantitative PCR. Expression of mRNA
encoding the proinflammatory cytokines IL-36g, IL-1b,
IL-17C, and IL-19 (Figure 3e) was significantly higher in ear
tissue of Card14DE138þ/e mice. Similar to human psoriatic
skin, Card14DE138þ/e murine tissue showed strong and
significantly increased expression of genes encoding the
S100 antimicrobial peptides S100a7 and S100a8 (Figure 3f);
b-defensins Defb3, Defb4, and Defb14 (Figure 3g); and the
chemokines Cxcl1, Cxcl2, and Ccl20 (Figure 3h). Expression
of filaggrin-1 and filaggrin-2 was also assessed and confirmed
RNA sequencing data, with an increase in filaggrin-1 (Flg)
and a decrease in filaggrin-2 (Flg2) in psoriatic tissue
(Figure 3i). Expression of caspase-14, which mediates pro-
filaggrin processing to form the cornified envelope, is also
increased in Card14DE138þ/e psoriatic tissue (Figure 3a
and b). Loss of filaggrin-1 expression is associated with anwww.jidonline.org 2015
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Figure 3. Transcriptome analysis of psoriatic tissue from ears of Card14DE138D/emice shows a gene signature typical of human plaque psoriasis. (aed) RNA
was extracted from 8-week-old Card14DE138þ/e heterozygous mice and wild-type littermates and subject to RNA sequencing analysis. (a) Heatmap showing
the 542 genes DEGs between three replicates of Card14DE138þ/e heterozygous mice and wild-type littermates. (b) Volcano plot showing the threshold for
significant genes from Card14DE138þ/e versus wild-type mice. A threshold of false discovery rate < 0.05 and log2 ratio > 2 or < e2 was chosen. Differentially
expressed genes of particular interest are labeled. (c) Dotplot showing the significantly enriched pathways from the Reactome. Each dot size represents the
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Figure 3. Continued
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CARD14 Mutation in Mice Drives Psoriasiform Diseaseepidermal barrier dysfunction, which grants microbes the
means to invade the epidermis, as in atopic dermatitis
(O’Regan et al., 2008). Robust expression of filaggrin-1 in
psoriatic tissue of Card14DE138þ/e mice is consistent with
the lack of any barrier defect in these mice (Figure 3j).
The CARD14/Bcl10 signaling axis is hyperactive in primary
keratinocytes from Card14DE138D/e mice
To determine whether the epidermal changes observed in
Card14DE138þ/e mice were due to dysregulated CARD14
function, epidermal tissue from ear pinnae of WT and
Card14DE138þ/e mice were stained for Bcl10 and CARD14
expression. Both molecules showed enhanced expression in
the epidermis from Card14DE138þ/e mice compared with
WT (Figure 4a). To further assess the CARD14/Bcl10 inter-
action in Card14DE138þ/e mice, primary keratinocytes were
isolated fromWTand Card14DE138þ/emouse epidermis and
cultured ex vivo. Murine keratinocytes were subject to lysis in
Triton X-100econtaining lysis buffer and soluble and insol-
uble fractions subject to SDS-PAGE (Figure 4b). CARD14 and
Bcl10 showed increased expression in the insoluble fraction
in Card14DE138þ/e-derived cells compared with WT controloverlap between the pathway and the gene set. The color represents the P-value
data from Card14DE138þ/e mice with online published data from human plaque
(NES) and adjusted P-value (padj) are indicated. (eei) RNAwas extracted from wh
measure mRNA expression levels of (e) Il1f9 (IL-36g), Il1b, Il17c, and Il19; (f) S10
and (i) Flg and Flg2. (j) Ear sections from 8-week-old Card14DE138þ/e and wild
isotype control. Black scale bar ¼ 100 mm; gray scale bar ¼ 50 mm. (aed) Analy
independent experiments with seven or eight mice per group (total n ¼ 15), and
0.01, ***P < 0.001, ****P < 0.0001. (j) Representative of eight individual mice pcells, which correlated with decreased expression in
the soluble fraction. Additionally, Bcl10 and CARD14
showed increased interaction as determined by co-
immunoprecipitation (Figure 4c) and enhanced processing
of Malt1 substrate protein RelB. Bcl10 expression was
visualized by confocal microscopy, and in primary kerati-
nocytes from WT mice, Bcl10 was expressed uniformly
throughout the cytoplasm; however, in keratinocytes from
Card14DE138þ/e mice Bcl10 was observed in discrete sig-
nalosome structures (Figure 4d). To assess the downstream
effects of this increased interaction, transcript levels of pro-
inflammatory molecules were assessed in keratinocytes
isolated and cultured from WT and Card14DE138þ/e mouse
epidermis by quantitative PCR. Levels of mRNA encoding
S100A7, IL-17C, IL-19, and IL-36g were significantly
increased in Card14DE138þ/e keratinocytes compared with
WT cells (Figure 4e).
Neutralization of the T helper type 17-polarizing cytokine
IL-23 p19 subunit attenuates disease symptoms
We next characterized the immune infiltrate of the skin of
Card14DE138þ/e mice. Psoriatic skin of Card14DE138þ/e. (d) Gene set enrichment analysis enrichment plots comparing transcriptome
psoriasis patients, GSE66511 and GSE54456. Normalized enrichment score
ole ear tissue of 5-week-old mice and subjected to quantitative PCR analysis to
0a7 and S100a8; (g) Defb3, Defb4, and Defb14; (h) Cxcl1, Cxcl2, and Ccl20;
-type littermates were stained with a specific antibody against filaggrin-1 or
sis of one experiment with three mice per group; (eei) representative of two
data were subjected to a two-tailed unpaired Student t test. *P < 0.05, **P <
er group. DEGs, differentially expressed genes; WT, wild type.
www.jidonline.org 2017
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Figure 4. Keratinocytes from Card14DE138D/e mice display enhanced CARD14/Bcl10 activity. (a) Confocal microscopy analysis of epidermal tissue from
ear pinnae from WT and Card14DE138þ/e mice stained for specific anti-Bcl10, -CARD14, or isotype control antibodies. Nuclei were stained with DAPI. Scale
bar ¼ 50 mm. (bee) Primary murine keratinocytes were isolated from WTand Card14DE138þ/e tail epidermis and cultured ex vivo for 3e4 days. (b) Cells were
lysed in Triton-Xecontaining buffer, and soluble and insoluble fractions were subject to SDS-PAGE followed by immunoblotting with indicated antibodies.
(c) Cell lysates were immunoprecipitated with an anti-Bcl10 antibody, followed by immunoblotting with indicated antibodies. DE ¼ keratinocytes from
Card14DE138þ/e mice. (d) Cells visualized for expression and localization of endogenous murine Bcl10 by confocal microscopy using a specific anti-Bcl10
antibody. Nuclei were stained with DAPI. Scale bar¼ 15 mm. (e) RNAwas extracted from whole ear tissue of 5-week-old mice and subjected to quantitative PCR
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CARD14 Mutation in Mice Drives Psoriasiform Diseasemice harbors a pronounced infiltrate of CD45-positive
leukocytes (Figure 5a). This immune infiltrate is composed
of increased numbers of neutrophils, myeloid antigen-
presenting cells, and gd and ab T cells compared with WT
littermates (Figure 5b, and see Supplementary Figure S5
online). T helper (Th) 17 cells play a central role in psoria-
sis pathogenesis, and IL-23 maintains the differentiation of
pathogenic Th17 cells, which secrete IL-17A and IL-22, two
of the cytokines that mediate the inflammatory effects and
hyperproliferation associated with human psoriasis (Cai et al.,
2012). Indeed, protein levels of IL-17A and IL-22 were
significantly increased in Card14DE138þ/e ear tissue of
adult mice (Figure 5c). IL-23p19, IL-17A, and IL-22e
encoding transcripts were also seen at significantly higher
levels in 5-week-old Card14DE138þ/e mouse skin
(Figure 5d). Similarly, the Th1 cytokines IFNg and TNF-a
were also significantly elevated in ear tissue of 5-week-old
Card14DE138þ/e mice (Figure 5e), contributing to an in-
flammatory milieu typical of human psoriasis.
To assess whether CARD14-induced psoriatic disease
symptoms can be attenuated in vivo by targeted disruption of
the IL-23/Th17 axis, Card14DE138þ/e heterozygous mice
were treated with a neutralizing antibody specific for the
murine IL-23p19 subunit by intraperitoneal injection over
the course of 15 days, and control mice were administered
an IgG isotype antibody. Mice receiving anti-IL-23p19e
neutralizing antibody showed a significantly decreased
psoriatic phenotype on the ears and tail after 2 weeks
of therapy (Figure 5f) and a significant reduction in ear
thickness versus at the onset of treatment and versus
IgG control animals (Figure 5g). Further reductions were
evident after administration of IL-23p19 over 3 weeks
(see Supplementary Figure S6aec online). Histological features
were assessed by the scoring system of Baker et al. (1992), and
IL-23p19etreatedmice showeda significant decrease inmurine
clinical score (Figure 5h and i). In vivo blockade of IL-23p19
also reduced expression of mRNA encoding b-defensins, S100
proteins, IL-36g, and IL-19 (Figure 5j). These results indicate
that disruption of the IL-23/Th17 immune signaling axis is
sufficient to reverse the aberrant epidermal signaling networks
induced by CARD14 GoF mutation. Thus, CARD14 GoF
drives IL-23emediated psoriatic skin disease, and targeting of
IL-23p19 in thismousemodel is a rapidandeffective therapeutic
option, consistent with reports from phase III clinical trials in
patientswithplaque-typepsoriasis (Nakamuraet al., 2017; Papp
et al., 2017; Reich et al., 2017).
DISCUSSION
Psoriasis is a common but complex inflammatory skin dis-
ease that arises from the interplay between stress or trauma
within the epidermis and a dysregulated immune response.
Genetic studies have shown a role for selected genes,
particularly those of the innate and adaptive immune system
and the IL-23/IL-17 signaling axis (Tsoi, 2012). Several genes
encoding proteins in epithelial barrier function have also
been linked to psoriasis susceptibility, and GoF mutations inanalysis of mRNA expression of S100a7, Il17c, Il19, and Il1f9 (IL-36g). (aed) Im
presented as the mean  standard error of the mean of three independent exper
**P < 0.01. IB, immunoblot; WT, wild type.the gene encoding the keratinocyte signaling molecule,
CARD14, have been associated with both psoriasis and PRP,
although the extent to which CARD14 genetic variants
contribute to disease susceptibility is currently unclear.
Here, we unequivocally show that CARD14 GoF alone is
sufficient to drive disease pathogenesis in vivo and show that
a single amino acid mutation of a key glutamic acid (E138)
results in the complete immunological and clinical pheno-
type of plaque-type psoriasis in mice. The etiology of psori-
asis has been elusive in the past, regarding the contribution of
keratinocyte dysfunction versus altered immune function
(Bos et al., 2005; Christophers, 1996). However, our data
strongly suggest that dysregulated keratinocyte signaling
pathways initiated by CARD14 contribute to drive the path-
ogenic IL-23/IL-17 axis in vivo. Card14DE138 heterozygous
mice spontaneously and rapidly developed a chronic psori-
atic phenotype with scaling skin lesions, epidermal acan-
thosis, parakeratosis, and hyperkeratosis, keratinocyte
hyperproliferation, and immune cell infiltration of lesional
skin. In addition to Card14DE138þ/e tissue recapitulating the
histological features of psoriasis, transcriptome profiling from
affected skin in these mice correlated with up-regulated and
down-regulated gene signatures observed in human plaque
psoriasis. In particular, high expression of antimicrobial
peptides (b-defensins, S100 proteins), chemokines (Cxcl2,
Ccl20), and cytokines (including IL-19, IL-36g, IL-1b, and
IL-23p19) were observed. Additionally, neutralization of
IL-23p19 significantly reduced skin lesions and the expres-
sion of anti-microbial peptides and proinflammatory cyto-
kines in the skin of Card14DE138 mice.
Tanaka et al. (2018) recently showed that CARD14-
deficient mice were protected from developing imiquimod-
induced psoriasiform disease (Tanaka et al., 2018), which is
consistent with our results that GoF mutation in CARD14 is
sufficient to drive the complete immunopathogenesis of
psoriatic disease in vivo. Tanaka’s study shows a role for
CARD14-positive hematopoietic cells in imiquimod-induced
psoriasiform disease. In our study, keratinocytes harboring
mutant CARD14 contribute to disease pathogenesis; how-
ever, it will be of interest to further tease out the interplay of
these different cell types in disease pathogenesis. Taken
together, these reports place CARD14 in a central role of
mediating psoriatic skin disease pathogenesis, which war-
rants further clinical appraisal. The physiological relevance to
human disease means that the Card14DE138þ/e mouse
model will become an invaluable tool for dissecting the
complex signaling networks associated with psoriatic skin
disease. This model will also be beneficial in the preclinical
assessment of therapeutics aimed at specifically targeting
molecular drivers of psoriasis and PRP in the future. These
findings highlight the formation of the CARD14/Bcl10/Malt1
complex as a key cellular process to target in the develop-
ment of future therapies for psoriatic disease. Malt1-specific
inhibitors have been suggested as a potential therapeutic
strategy that can be used for treating psoriatic skin disease,
because inhibition of Malt1 function would have the benefitages are representative of three independent experiments or (e) data are
iments and were subjected to a two-tailed unpaired Student t test. *P < 0.05,
www.jidonline.org 2019
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Figure 5. Immune cell infiltrate shows a T helper type 17 signature, and IL-23p19 neutralization ameliorates the phenotype in Card14DE138D/e mice. (a, b)
Flow cytometry analysis of single-cell suspension from ear tissue from age- and sex-matched adult Card14DE138þ/emice and littermate controls. Shown are the
number of (a) CD45þ hematopoietic cells and (b) neutrophils (CD11bþLy6Gþ), inflammatory (CD11bþLy6GeNK1.1eMHCIIhiLy6Chi) and noninflammatory
(CD11bþLy6GeNK1.1eMHCIIhiLy6Ce) APCs, ab T cells (CD3lowTCRbþ), and gd T cells (CD3lowTCRbe) per ear. (c) Whole ears from age- and sex-matched adult
Card14DE138þ/e and wild-type mice were homogenized and analyzed for IL-17A and IL-22 protein levels by ELISA (n ¼ 8). (d, e) RNA was extracted from
whole ear tissue of 5-week-old mice and subjected to quantitative PCR analysis of (d) Il23p19, Il17a, and Il22 or (e) Ifng (IFNg) and Tnfa mRNA expression
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CARD14 Mutation in Mice Drives Psoriasiform Diseaseof affecting T-cell and keratinocyte function (downstream of
CARD11 and CARD14, respectively) (Van Nuffel et al.,
2017). Targeting CARD14 directly, however, may permit the
development of more specific therapies with decreased
adverse effect profiles, and this merits further investigation
into understanding CARD14 biology.
MATERIALS AND METHODS
Details of the materials and methods are given in the Supplementary
Materials online.
Genetically modified mouse strains
To generate Card14DE138mice, C57BL/6J (JR 000664) oocytes were
microinjected with Cas9 mRNA and donor DNA along with one of
two guide RNA sequences. Two strains harboring the Card14DE138
deletion were generated from separate founder animals, strains
28900 (C57BL/6J-Card14em9(delE138)Lutzy/J) and 28882 (C57BL/
6J-Card14em5(delE138)Lutzy/J). Mouse strain 28900 was used for
the experiments described in the article. All animal experiments
were performed in accordance with the regulations and guidelines
of and with ethical approval from the Cantonal Veterinary Office of
Zu¨rich, Switzerland.
Cell culture
Human primary keratinocytes were cultured as previously described
(Feldmeyer et al., 2007). Briefly, human primary foreskin keratino-
cytes were passaged in keratinocyte serum-free medium (Thermo
Fisher Scientific, Waltham, MA), supplemented with epithelial
growth factor and bovine pituitary extract (Thermo Fisher Scientific),
and seeded for experiments after 3 passages. All cells were main-
tained at 37 C in a humidified atmosphere of 5% CO2.
RNA sequencing transcriptome analysis
RNAwas extracted from whole ear tissue from 8-week-old female WT
and Card14DE138þ/e mice. After library preparation, samples were
analyzed with the Illumina HiSeq 4000 (Illumina, San Diego, CA),
which was used to generate single end reads of length 125 nucleo-
tides. For data processing, the raw reads were first cleaned by
removing adapter sequences, trimming low-quality ends, and filtering
reads with low quality (phred quality < 20) using Trimmomatic
(Bolger et al., 2014). Sequence alignment of the resulting high-quality
reads to the Mus musculus reference genome (build GRCm38) and
quantification of gene level expression was carried out using RSEM,
version 1.3.0 (Li and Dewey, 2011). Differential expression was
computed using the generalized linear model implemented in the
Bioconductor package EdgeR, version 3.20.1 (Robinson et al., 2010).
The data was deposited in the European Nucleotide Archive (acces-
sion number PRJEB25394). Pathway analysis was performed using
ReactomePA (Yu and He, 2016). The top significant pathways were
plotted as a dotplot. Gene set enrichment analysis was performed
using fgsea (Sergushichev, 2016), and datasets from GSE66511 andlevels. (f) Macroscopic images of ears and tails of IgG- and IL-23p19etreated m
IL-23p19etreated animals and control animals at days 0, 6, 10, and 15 of the e
histological features shown by hematoxylin and eosin staining at day 15. Scale
IL-23p19etreated mice. (j) quantitative PCR analysis of mRNA expression of De
and IgG-treated mice. Data are representative of (a, b) three independent experi
independent experiments with seven or eight mice per group. Total n ¼ 15. (f) Im
group) or (gej) data are presented as the mean  standard error of the mean of six
and were subjected to a two-tailed unpaired Student t test. *P < 0.05, **P < 0.01GSE54456 were obtained from the National Center for Biotechnology
Information Gene Expression Omnibus.
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